Cytomegalovirus (HHV-5) Infections Pipeline Review Market Growth & Analysis Report 2015 Radiant Insights, Inc
Summary Radiant Insights's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. Read Complete Report with TOC @ http://www.radiantinsights.com/research/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015 Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Summary
Radiant Insights's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015
Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
China Biologic Products, <strong>Inc</strong>. 34<br />
CyTuVax B.V. 35<br />
GlaxoSmithKline Plc 36<br />
Hookipa Biotech AG 37<br />
Humabs BioMed SA 38<br />
iQur Limited 39<br />
Kadmon Corporation, LLC 40<br />
Lead Discovery Center GmbH 41<br />
Merck & Co., <strong>Inc</strong>. 42<br />
Microbiotix, <strong>Inc</strong>. 43<br />
Novartis AG 44<br />
Pfizer <strong>Inc</strong>. 45<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
Phoenix Biotechnology, <strong>Inc</strong>. 46<br />
Savoy Pharmaceuticals, <strong>Inc</strong>. 47<br />
Trellis Bioscience, <strong>Inc</strong>. 48<br />
Vakzine Projekt Management GmbH 49<br />
VBI Vaccines <strong>Inc</strong>. 50<br />
Vical <strong>Inc</strong>orporated 51<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Therapeutics Assessment 52<br />
Assessment by Monotherapy Products 52<br />
Assessment by Combination Products 53<br />
Assessment by Target 54<br />
Assessment by Mechanism of Action 56<br />
Assessment by Route of Administration 58<br />
Assessment by Molecule Type 60<br />
Drug Profiles 62
Change language